MFJ Stock Chart & Stats
€0.60
€0.01(0.84%)
At close: 4:00 PM EST
€0.60
€0.01(0.84%)
Day’s Range― - ―
52-Week Range€0.46 - €0.77
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€380.11M
Enterprise Value€624.48M
Total Cash (Recent Filing)€35.47M
Total Debt (Recent Filing)€17.61M
Price to Earnings (P/E)82.5
Beta1.14
Next Earnings
Mar 02, 2027EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.95
Price to Book (P/B)7.01
Price to Sales (P/S)4.42
P/FCF Ratio67.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.72Price Target Upside20.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€101.09M
Bulls Say, Bears Say
Bulls Say
Broad Revenue And Account ExpansionSustained product growth and expanding hospital adoption indicate that PolyNovo is deepening its commercial footprint rather than relying on a narrow customer base. Broader account penetration can support recurring utilization, improve market access, and create a durable foundation for future international growth.
Rapid MTX AdoptionMTX is scaling substantially faster than the broader business, providing a meaningful product-led growth driver and evidence of customer acceptance. Expansion across accounts and geographies can diversify the portfolio, strengthen the NovoSorb platform, and support continued revenue growth over coming quarters.
Improving Balance-sheet StrengthLower leverage alongside substantial equity growth gives PolyNovo greater financial flexibility to fund capacity, research, and commercial expansion without excessive dependence on debt. The stronger balance sheet also improves resilience if operating conditions or investment requirements become less favorable.
Bears Say
Profitability And Margin VolatilityAlthough PolyNovo is profitable, the decline in net margin and wide variation in gross margin show that earnings quality and cost structure are not yet consistently stable. Continued volatility could limit operating leverage, make results harder to forecast, and reduce the durability of reported profit growth.
Uneven Cash-flow ConversionThe rebound in cash generation is encouraging, but the recent swings and modest conversion of earnings into free cash flow indicate that working capital and investment needs remain material. If this pattern persists, internally generated cash may be less reliable for funding expansion and shareholder returns.
Regulatory And Reimbursement Execution RiskCommercial expansion into outpatient care and broader U.S. promotion depends on reimbursement confidence and regulatory progress, creating an execution constraint beyond product demand alone. Delays or unfavorable policy developments could slow adoption, extend commercialization timelines, and defer the benefits of planned growth initiatives.
Polynovo News
MFJ FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest stock price was €0.46 and its highest was €0.77 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is €380.11M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Mar 02, 2027 which is in 124 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Aug 25, 2026. The company reported €0.007 earnings per share for the quarter, beating the consensus estimate of €0.005 by €0.002.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is <0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of €0.007 in its last earnings report, beating expectations of €0.005. Following the earnings report the stock price went down -4.918%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in DE:MFJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€0.72 (20.69% Upside)
€0.72 (20.69% Upside)
Blogger Sentiment
Bullish
DE:MFJ Sentiment 95%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.90%
12-Months-Change
Fundamentals
Return on Equity
8.45%
Trailing 12-Months
Asset Growth
8.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Polynovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
MFJ Company Deck
MFJ Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates strong commercial momentum across products (notably MTX), significant sales and adjusted EBITDA growth, positive cash generation and strategic investments (new facility, strengthened leadership, clinical evidence). Several manageable near-term headwinds were disclosed: FX volatility, one-off impacts from an R&D lab fire, lumpy large-burn case volumes affecting H2 U.S. growth, reimbursement turbulence for outpatient launches, and timing risks tied to PMA approval and facility transition. Overall the positives (robust growth rates, record months, strong cash flow, substantial MTX adoption and regulatory progress) materially outweigh the challenges, which are largely operational, timing or one-off in nature.View all DE:MFJ earnings summariesMFJ Stock 12 Month Forecast
Average Price Target
€0.72
▲(20.69% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―